The underlying mechanism might be that cediranib could increase tumor hypoxia and inhibit platelet-derived growth factor receptor to downregulate BRCA1/2 and RAD51, thus decreasing a homology-deficient DNA repair to confer olaparib sensitivity [120]. This evidence concerns the gene BRCA1 and neoplasm.